MICRONEEDLE COATED WITH DRUG AND MANUFACTURING METHOD FOR SAME

Abstract

The present invention relates to a drug-coated microneedle and a method of manufacturing the same, and more particularly to a drug-coated microneedle that delivers a drug by physically piercing the stratum corneum of the skin and a method of manufacturing the same. The drug-coated microneedle is represented by Chemical Formula 1 below, and is capable of releasing a drug through a redox reaction after penetration into the skin. The drug-coated microneedle according to the present invention is capable of effectively delivering a drug having excellent functionality but low skin permeability, and is thus useful as a material for functional cosmetics for whitening, wrinkle reduction, inflammation reduction and the like. [Chemical Formula 1] MN-S—S-D. In Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.

Claims

1. A method of manufacturing a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into a skin, comprising: (a) manufacturing a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group by modifying a surface of a silica-(SiO.sub.2)-containing microneedle; (b) manufacturing a drug having a sulfhydryl (—SH) functional group by binding a drug with a linker having a sulfhydryl (—SH) functional group; and (c) subjecting the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction: [Chemical Formula 1] MN-S—S-D in Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.

2. The method of claim 1, wherein the silica-(SiO.sub.2)-containing microneedle is an acicular spicule derived from a sponge.

3. The method of claim 1, wherein the modifying the surface of the silica-(SiO.sub.2)-containing microneedle is performed by subjecting the silica-(SiO.sub.2)-containing microneedle to stirring with any one selected from the group consisting of (3-mercaptopropyl)methyldimethoxysilane, (3-mercaptopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]ethylenediamine, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and 3,3′-dithiodipropionic acid.

4. The method of claim 1, wherein the drug having the sulfhydryl (—SH) functional group is at least one selected from the group consisting of Chemical Formulas 2 to 8 below: [Chemical Formula 2]: Lys-His-Gly-X [Chemical Formula 3]: Gly-His-Lys-X [Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X [Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X [Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X [Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X ##STR00010## in Chemical Formulas 2 to 8, X is at least one selected from the group consisting of thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and cysteine.

5. The method of claim 1, wherein the oxidation reaction of the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group is performed using at least one oxidant selected from the group consisting of iodine, potassium phosphate, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), dehydroascorbic acid, hydrogen peroxide (H.sub.2O.sub.2), and oxygen (O.sub.2).

6. A drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into a skin: [Chemical Formula 1] MN-S—S-D in Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.

7. The drug-coated microneedle of claim 6, wherein the silica-(SiO.sub.2)-containing microneedle is an acicular spicule derived from a sponge.

8. The drug-coated microneedle of claim 6, wherein the microneedle represented by Chemical Formula 1 is manufactured by attaching a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group and a drug having a sulfhydryl (—SH) functional group to each other.

9. The drug-coated microneedle of claim 8, wherein the silica-(SiO.sub.2)-containing microneedle includes the sulfhydryl (—SH) functional group in an amount of 0.8×10.sup.−6 mol/g to 10×10.sup.−6 mol/g.

10. The drug-coated microneedle of claim 8, wherein the drug having the sulfhydryl (—SH) functional group is at least one selected from the group consisting of Chemical Formulas 2 to 8 below: [Chemical Formula 2]: Lys-His-Gly-X [Chemical Formula 3]: Gly-His-Lys-X [Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X [Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X [Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X [Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X ##STR00011## in Chemical Formulas 2 to 8, X is at least one selected from the group consisting of thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and cysteine.

11. A cosmetic composition comprising the microneedle of claim 6.

12. The cosmetic composition of claim 11, wherein a cosmetic is selected from the group consisting of a softening lotion, nourishing lotion, nourishing cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, and powder.

13. A cosmetic composition comprising the microneedle of claim 7.

14. A cosmetic composition comprising the microneedle of claim 8.

15. A cosmetic composition comprising the microneedle of claim 9.

16. A cosmetic composition comprising the microneedle of claim 10.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0032] FIG. 1 is SEM and microscope images of a silica-(SiO.sub.2)-containing microneedle purified according to an embodiment of the present invention;

[0033] FIG. 2 shows graphs showing the results of measurement of the molar number of a sulfhydryl (—SH) functional group per g of a microneedle having a sulfhydryl (—SH) functional group manufactured according to an embodiment of the present invention;

[0034] FIG. 3 is a graph showing the results of evaluation of cytotoxicity of a drug having a sulfhydryl (—SH) functional group manufactured according to an embodiment of the present invention;

[0035] FIG. 4 shows graphs showing the results of evaluation of collagen production capability of the drug having the sulfhydryl (—SH) functional group manufactured according to an embodiment of the present invention;

[0036] FIG. 5 is a graph showing the results of evaluation of collagen production capability of the drug detached from the microneedle depending on the type of sulfhydryl (—SH) functional group;

[0037] FIG. 6 is a graph showing the results of evaluation of collagen production capability of the drug depending on the amount of GSH (glutathione); and

[0038] FIG. 7 is microscope images showing the wrinkle reduction effect of a cream manufactured according to an embodiment of the present invention.

BEST MODE

[0039] When a drug having excellent functionality but low skin permeability is attached to a microneedle through disulfide bonding, the drug penetrates into the stratum corneum of the skin along with the microneedle and is then released through a redox reaction, so the present invention is intended to confirm that the drug can be effectively delivered.

[0040] In the present invention, a drug-coated microneedle is manufactured by modifying the surface of a microneedle derived from an animal sponge to afford a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group, binding a drug with a linker having a sulfhydryl (—SH) functional group to afford a drug having a sulfhydryl (—SH) functional group, and performing an oxidation reaction therebetween. Based on the results of evaluation of cytotoxicity and collagen production capability of the drug-coated microneedle thus manufactured, it is confirmed that the drug-coated microneedle has no cytotoxicity but has superior collagen production effects.

[0041] Therefore, an aspect of the present invention pertains to a method of manufacturing a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into the skin, including: (a) manufacturing a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group by modifying the surface of a silica-(SiO.sub.2)-containing microneedle; (b) manufacturing a drug having a sulfhydryl (—SH) functional group by binding a drug with a linker having a sulfhydryl (—SH) functional group; and (c) subjecting the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction.

[0042] [Chemical Formula 1]

[0043] MN-S—S-D

[0044] In Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.

[0045] In the present invention, the silica-(SiO.sub.2)-containing microneedle may be an acicular spicule derived from a sponge. Examples of the sponge may include, but are not limited to, Spongilla lacustris, Spongilla fragilis, Ephydatia fluviatilis, and the like.

[0046] The size of the acicular spicule is not particularly limited, and an acicular spicule having a length of about 100 to 300 μm and a width of about 10 to 30 μm may be used.

[0047] The silica-(SiO.sub.2)-containing microneedle that is used is preferably one purified in a manner in which an acicular spicule powder derived from a sponge is sequentially added with sulfuric acid and sodium hydroxide, stirred, filtered, and washed. FIG. 1 is SEM and microscope images of the silica-(SiO.sub.2)-containing microneedle purified according to an embodiment of the present invention.

[0048] In order to penetrate into the skin, the drug, such as a peptide, which alone has difficulty penetrating into the skin, has to be attached to the microneedle. In order to attach the drug to the microneedle through disulfide bonding, a sulfhydryl (—SH) functional group has to be introduced to each of the drug and the microneedle.

[0049] First, in the present invention, a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group is manufactured by modifying the surface of a silica-(SiO.sub.2)-containing microneedle.

[0050] Here, the modifying the surface of the silica-(SiO.sub.2)-containing microneedle is performed by subjecting the silica-(SiO.sub.2)-containing microneedle to stirring with any one selected from the group consisting of (3-mercaptopropyl)methyldimethoxysilane, (3-mercaptopropyl)trimethoxysilane, N-[3-(trimethoxysilyl)propyl]ethylenediamine, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and 3,3′-dithiodipropionic acid.

[0051] Although varying depending on the shape of the microneedle, the type of mercaptosilane for surface modification, and the reaction conditions, the silica-(SiO.sub.2)-containing microneedle thus manufactured may include the sulfhydryl (—SH) functional group in an amount of 0.8×10.sup.−6 mol/g to 10×10.sup.−6 mol/g, and preferably in an amount exceeding 2.0×10.sup.−6 mol/g, taking into consideration the surface area of the microneedle.

[0052] In the present invention, a drug having a sulfhydryl (—SH) functional group is manufactured by binding a drug with a linker having a sulfhydryl (—SH) functional group.

[0053] As the drug, any material may be used without particular limitation, so long as it penetrates into the skin and is capable of increasing skin improvement effects, such as skin-soothing effects, vitality enhancement effects, antioxidant effects, whitening effects, moisturizing effects, skin regeneration effects, anti-aging effects, anti-inflammatory effects, collagen synthesis promotion effects, and the like. Not only a synthetic compound but also a peptide may be used.

[0054] Examples of the linker having the sulfhydryl (—SH) functional group may include, but are not limited to, thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, cysteine, and the like.

[0055] When the drug is a peptide, the use of cysteine as the linker may cause the properties thereof to vary depending on the amino acid sequence and structure, and thus the use of thioglycolic acid, 3-mercaptopropionic acid or 11-mercaptoundecanoic acid is preferable, with the use of thioglycolic acid, having a low molecular weight, being most preferable.

[0056] In the present invention, examples of the drug having the sulfhydryl (—SH) functional group manufactured by binding the peptide or compound drug with the linker having the sulfhydryl (—SH) functional group may include, but are not limited to, Chemical Formulas 2 to 8 below.

[0057] [Chemical Formula 2]: Lys-His-Gly-X

[0058] [Chemical Formula 3]: Gly-His-Lys-X

[0059] [Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X

[0060] [Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X

[0061] [Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X

[0062] [Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X

##STR00002##

[0063] In Chemical Formulas 2 to 8, X is at least one selected from the group consisting of thioglycolic acid, 3-mercaptopropionic acid, 11-mercaptoundecanoic acid, and cysteine.

[0064] In the present invention, a drug-coated microneedle is manufactured by subjecting the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to an oxidation reaction.

[0065] As the oxidant for the oxidation reaction, any material may be used without particular limitation, so long as it is able to attach the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group and the drug having the sulfhydryl (—SH) functional group to each other through oxidation. Examples of the oxidant may include iodine, potassium phosphate, 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ), dehydroascorbic acid, hydrogen peroxide (H.sub.2O.sub.2), oxygen (O.sub.2), and the like.

[0066] In the present invention, a drug-coated microneedle capable of releasing a drug through a redox reaction after penetration into the skin is manufactured using the above method.

[0067] Therefore, another aspect of the present invention pertains to a drug-coated microneedle, which is represented by Chemical Formula 1 below and in which a drug is released through a redox reaction after penetration into the skin.

[0068] [Chemical Formula 1]

[0069] MN-S—S-D

[0070] In Chemical Formula 1, MN is a silica-(SiO.sub.2)-containing microneedle, S—S is a disulfide bond, and D is a drug.

[0071] In addition, the present invention pertains to a cosmetic composition including the drug-coated microneedle.

[0072] The amount of the drug-coated microneedle may vary depending on the type of cosmetic, and may be 0.1 to 10.0 wt % based on the total weight of the cosmetic composition.

[0073] Examples of the cosmetics may include, but are not limited to, a softening lotion, nourishing lotion, nourishing cream, massage cream, essence, ampoule, gel, eye cream, cleansing cream, cleansing foam, cleansing water, pack, spray, powder, and the like.

[0074] In the cosmetic composition, other ingredients may be appropriately combined within a range that does not impair the purpose according to the present invention depending on the type or purpose of use of the formulation, in addition to the drug-coated microneedle.

[0075] Moreover, depending on the quality or function of the final product, the cosmetic composition may further include materials typically used in the art, such as fatty materials, organic solvents, solubilizers, thickeners, gelling agents, emollients, antioxidants, suspension agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or nonionic emulsifiers, fillers, metal-ion-sequestering agents, chelating agents, preservatives, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic activating agents, and adjuvants commonly used in the cosmetic or dermatological field, such as any other ingredients commonly used in cosmetic compositions.

[0076] Here, it is preferable that the adjuvants and the mixing ratio thereof be appropriately selected so as not to affect the desirable properties of the cosmetic composition according to the present invention.

Mode for Invention

[0077] A better understanding of the present invention will be given through the following examples. These examples are merely set forth to illustrate the present invention, and are not to be construed as limiting the scope of the present invention, as will be apparent to those skilled in the art.

Example 1: Manufacture of Drug-Coated Microneedle

[0078] 1-1: Purification of Silica-(SiO.sub.2)-Containing Microneedle

[0079] An acicular spicule (289 g) derived from Spongilla fragilis Leidy and sulfuric acid (80 g) were placed in a reactor, stirred for 1 hr, added with water, further stirred, and filtered. The acicular spicule was washed with water, further stirred for 1 to 2 hr, added with NaOH and HNO.sub.3, stirred, adjusted to a pH of 6 to 8, and washed with water. Finally, the acicular spicule was washed with ethanol, filtered, and dried.

[0080] 1-2: Surface Modification of Silica-(SiO.sub.2)-Containing Microneedle

[0081] In order to introduce a sulfhydryl (—SH) functional group to the purified acicular spicule (silica-(SiO.sub.2)-containing microneedle), hydrolysis and dealkoxylation were performed.

[0082] 1-2-1: Surface Modification Using Hydrolysis

[0083] As shown in [Scheme 1] below, 10 g of the purified microneedle, 0.1 to 3.0 ml of (3-mercaptopropyl)trimethoxysilane (MPTMS), and 100 g of a mixed water/ethanol solution (50% ethanol) were placed in a reactor and then allowed to react at room temperature for 4 hr. The resulting reaction product was washed and then dried under reduced pressure at 70° C. for 4 hr, thus obtaining a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group (No. 1).

##STR00003##

[0084] 1-2-2 to 1-2-4: Surface Modification Using Hydrolysis

[0085] The reaction was carried out under the conditions of Example 1-2-1, with the exception that the reaction time was changed to 8, 16 and 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO.sub.2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 2 to 4).

[0086] 1-2-5 and 1-2-6: Surface Modification Using Hydrolysis

[0087] The reaction was carried out under the conditions of Example 1-2-1, with the exception that the reaction temperature was adjusted to 40° C. and 60° C. and the reaction time was changed to 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO.sub.2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 5 and 6).

[0088] The molar number of the sulfhydryl (—SH) functional group per g of the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group obtained as described above was measured using a spectrophotometer (Agilent 8453 UV Spectrophotometer) through an Ellman assay. The results thereof are shown in Table 1 below and in FIG. 2.

TABLE-US-00001 TABLE 1 —SH —SH SH molar —SH molar molar molar number for concentration number number 1 g of MN No. Abs.(412) (M) (mol) (μmol) (μmol) 1 0.08928 6.3095.E−06 1.3881.E−08 0.0139 0.9132 2 0.08963 6.3343.E−06 1.3935.E−08 0.0139 0.9229 3 0.09669 6.8332.E−06 1.5033.E−08 0.0150 1.0157 4 0.11959 8.4516.E−06 1.8593.E−08 0.0186 1.2396 5 0.12579 8.8898.E−06 1.9557.E−08 0.0196 1.2867 6 0.16510 1.1668.E−05 2.5669.E−08 0.0257 1.7344

[0089] As is apparent from Table 1 and FIG. 2, the —SH molar number for 1 g of MN was determined to be 0.9132 to 1.7344 μmol/g depending on the reaction temperature and the reaction time.

[0090] 1-2-7: Surface Modification using Dealkoxylation

[0091] As shown in [Scheme 2] below, 5.02 g of the purified microneedle, 0.1 to 3.0 ml of (3-mercaptopropyl)trimethoxysilane (MPTMS), and 50 g of toluene were placed in a reactor and then allowed to react at 90° C. for 4 hr. The resulting reaction product was washed and then dried under reduced pressure at 70° C. for 20 hr, thus obtaining a silica-(SiO.sub.2)-containing microneedle having a sulfhydryl (—SH) functional group (No. 1).

##STR00004##

[0092] 1-2-8 to 1-2-10: Surface Modification Using Dealkoxylation

[0093] The reaction was carried out under the conditions of Example 1-2-7, with the exception that the reaction time was changed to 8, 16 and 24 hr. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO.sub.2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 2 to 4).

[0094] 1-2-11 and 1-2-12: Surface Modification Using Dealkoxylation

[0095] The reflux reaction was carried out under the conditions of Example 1-2-7, with the exception that the reaction time was changed to 16 and 24 hr at a pH of 2 to 3. After the reaction, the resulting reaction product was dried under reduced pressure at 70° C. for 4 hr, thus obtaining silica-(SiO.sub.2)-containing microneedles having sulfhydryl (—SH) functional groups (Nos. 5 and 6).

[0096] The molar number of the sulfhydryl (—SH) functional group per g of the silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group obtained as described above was measured using a spectrophotometer (Agilent 8453 UV Spectrophotometer) through an Ellman assay. The results thereof are shown in Table 2 below and in FIG. 2.

TABLE-US-00002 TABLE 2 —SH —SH SH molar —SH molar molar molar number for concentration number number 1 g of MN No. Abs.(412) (M) (mol) (μmol) (μmol) 1 0.0702 4.962E−06 1.092E−08 0.01092 0.9786 2 0.0816 5.764E−06 1.268E−08 0.11268 0.9853 3 0.1346 9.516E−06 2.093E−08 0.02093 1.791 4 0.1345 9.502E−06 2.091E−08 0.02091 1.772 5 0.6658 4.706E−05 1.035E−07 0.1035 8.855 6 0.7859 5.554E−05 1.222E−07 0.1222 10.055

[0097] As is apparent from Table 2 and FIG. 2, the —SH molar number for 1 g of MN was determined to be 0.9786 to 10.055 μmol/g, depending on the reaction temperature and the reaction time.

[0098] 1-3: Binding of Drug with Linker having Sulfhydryl (—SH) Functional Group

[0099] 1-3-1: Binding of Peptide Drug with Linker

[0100] The names and abbreviations of the amino acids used in the present invention are set forth below.

[0101] Lys: lysine/His: histidine/Gly: glycine/Ser: serine/Thr: threonine/Arg: arginine/Gln: glutamine/Met: methionine/Glu: glutamic Acid

[0102] 1-3-1-1: Preparation of Sulfhydryl-Tripeptides Represented by Chemical Formula 2 and Chemical Formula 3

[0103] As shown in methods (1) to (6) below and in [Scheme 3] below, the peptides were continuously coupled according to the same synthesis cycle. Specifically, the following amino acids in the order of amino acid sequences of compounds 2 and 3 were placed in a reaction vessel and peptide bonding progressed, and finally, a linker X having a sulfhydryl (—SH) functional group [thioglycolic acid (TA), 3-mercaptopropionic acid (MPA), 11-mercaptoundecanoic acid (MUD) and cysteine (CS)] was added thereto and amide bonding progressed, thus preparing sulfhydryl-tripeptides represented by Chemical Formula 2 and Chemical Formula 3.

[0104] (1) Washing three times with DMF solvent (10 mL)/washing three times with dichloromethane (DCM) solvent (10 mL)

[0105] (2) Deprotection two times for 10 min using 20% (w/v) piperidine DMF solution (3 mL)

[0106] (3) Washing five times with DMF solvent (10 mL)

[0107] (4) Fmoc-amino acid addition

[0108] (5) Amino acid activation and coupling for 2 hr by adding coupling reagent

[0109] (6) Washing five times with DMF solvent (10 mL)

[0110] [Chemical Formula 2]: Lys-His-Gly-X

[0111] [Chemical Formula 3]: Gly-His-Lys-X

##STR00005##

[0112] 1-3-1-2: Preparation of Sulfhydryl-Pentapeptides Represented by Chemical Formula 4 and Chemical Formula 5

[0113] Sulfhydryl-pentapeptides represented by Chemical Formula 4 and Chemical Formula 5 were prepared through the peptide synthesis method described in 1-3-1-1 above and as shown in [Scheme 4] below.

[0114] [Chemical Formula 4]: Ser-Lys-Thr-Thr-Lys-X

[0115] [Chemical Formula 5]: Lys-Thr-Thr-Lys-Ser-X

##STR00006##

[0116] 1-3-1-3: Preparation of Sulfhydryl-Hexapeptides Represented by Chemical Formula 6 and Chemical Formula 7

[0117] Sulfhydryl-hexapeptides represented by Chemical Formula 6 and Chemical Formula 7 were prepared through the peptide synthesis method described in 1-3-1-1 above and as shown in [Scheme 5] below.

[0118] [Chemical Formula 6]: Arg-Arg-Gln-Met-Glu-Glu-X

[0119] [Chemical Formula 7]: Glu-Glu-Met-Gln-Arg-Arg-X

##STR00007##

[0120] 1-3-2: Binding of Synthetic Compound Drug with Linker

[0121] As shown in [Scheme 6] below, dehydroascorbic acid was reacted with a lipase and a linker X having a sulfhydryl (—SH) functional group [thioglycolic acid (TA), 3-mercaptopropionic acid (MPA), 11-mercaptoundecanoic acid (MUD) and cysteine] and reduced, thus preparing a synthetic compound having a sulfhydryl (—SH) functional group, as represented by Chemical Formula 8 below.

##STR00008##

##STR00009##

[0122] 1-4: Manufacture of Microneedle having Drug Attached thereto through Disulfide Bonding

[0123] The silica-(SiO.sub.2)-containing microneedle having the sulfhydryl (—SH) functional group manufactured in Example 1-2 and the drug having the sulfhydryl (—SH) functional group manufactured in Example 1-3 were subjected to an oxidation reaction and thus attached to each other through disulfide bonding.

[0124] 1-4-1: Attachment of Peptide Drug

[0125] 1-4-1-1: Disulfide Bonding through Oxidation using Iodine

[0126] 0.3 g of the sulfhydryl microneedle manufactured in Example 1-2 and 5.0 mL of purified water/ethanol (50% ethanol) were placed in a reaction vessel and stirred for 60 min so that the microneedle was uniformly dispersed, after which 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.) was added thereto, 1.2 μmol of the peptide of each of Chemical Formulas 2 to 7 prepared in Example 1-3-1 was added thereto, and the resulting mixture was stirred. After termination of the reaction, washing five times or more with 5.0 mL of ethanol and drying under reduced pressure at 25° C. for 12 hr were performed, thus manufacturing a microneedle having a peptide attached thereto through disulfide bonding.

[0127] 1-4-1-2: Disulfide Bonding through Oxidation using Potassium Phosphate

[0128] A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of purified water was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 40.8 μg (0.3 μmol) of potassium phosphate (KH.sub.2PO.sub.4, molar molecular weight: 136.06 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0129] 1-4-1-3: Disulfide Bonding through Oxidation using DDQ

[0130] A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of dichloromethane was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 68.1 μg (0.3 μmol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ, molar molecular weight: 227.0 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0131] 1-4-1-4: Disulfide Bonding through Oxidation Using Dehydroascorbic Acid

[0132] A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of a 0.2 M sodium acetate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 52.84 μg (0.3 μmol) of dehydroascorbic acid (molar molecular weight: 174.11 g/mol) was used in lieu of 12.7 μg (0.5 mol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0133] 1-4-1-5: Disulfide Bonding through Oxidation Using Hydrogen Peroxide

[0134] A microneedle having a peptide attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-1-1, with the exception that 5.0 mL of a 0.2 M sodium phosphate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 10 μL of 30% hydrogen peroxide was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0135] 1-4-2: Attachment of Synthetic Compound Drug

[0136] 1-4-2-1: Disulfide Bonding through Oxidation Using Iodine

[0137] 0.3 g of the sulfhydryl microneedle manufactured in Example 1-2 and 5.0 mL of purified water/ethanol (50% ethanol) were placed in a reaction vessel and stirred for 60 min so that the microneedle was uniformly dispersed, after which 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.) was added thereto, 112.6 μg (0.45 μmol) of the compound of Chemical Formula 8 prepared in Example 1-3-2 was added thereto, and the resulting mixture was stirred. After termination of the reaction, washing five times or more with 5.0 mL of purified water and ethanol and drying under reduced pressure at 70° C. for 12 hr were performed, thus manufacturing a microneedle having ascorbic acid attached thereto through disulfide bonding.

[0138] 1-4-2-2: Disulfide Bonding through Oxidation Using Potassium Phosphate

[0139] A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of purified water was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 40.8 μg (0.3 μmol) of potassium phosphate (KH.sub.2PO.sub.4, molar molecular weight: 136.06 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0140] 1-4-2-3: Disulfide Bonding through Oxidation Using DDQ

[0141] A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of dichloromethane was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 68.1 μg (0.3 μmol) of 2,3-dichloro-5,6-dicyano-p-benzoquinone (DDQ, molar molecular weight: 227.0 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0142] 1-4-2-4: Disulfide Bonding through Oxidation Using Dehydroascorbic Acid

[0143] A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of a 0.2 M sodium acetate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 52.84 μg (0.3 μmol) of dehydroascorbic acid (molar molecular weight: 174.11 g/mol) was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0144] 1-4-2-5: Disulfide Bonding through Oxidation Using Hydrogen Peroxide

[0145] A microneedle having ascorbic acid attached thereto through disulfide bonding was manufactured in the same manner as in 1-4-2-1, with the exception that 5.0 mL of a 0.2 M sodium phosphate buffer was used in lieu of 5.0 mL of purified water/ethanol (50% ethanol) and 10 μL of 30% hydrogen peroxide was used in lieu of 12.7 μg (0.5 μmol) of iodine (I.sub.2, molar molecular weight: 253.81, Tokyo Chemical Industry Co. Ltd.).

[0146] Experimental Example 1: Evaluation of Collagen Synthesis Promotion Capability of Drug having Sulfhydryl (—SH) Functional Group

[0147] 1-1: Cell Line Selection and Culture

[0148] Fibroblasts (CCD-986SK) purchased from the Korea Cell Line Bank were seeded to the bottom of a culture dish, after which DMEM (Dulbecco's Modified Eagle's Medium) containing penicillin (100 IU/mL), streptomycin (100 μg/mL) and 10% fetal bovine serum (FBS) was added thereto, followed by culture in a 5% CO.sub.2 incubator at 37° C.

[0149] 1-2: Cytotoxicity Test Method (CCK Assay)

[0150] Fibroblasts (CCD-986SK) were aliquoted in an amount of 1.0×10.sup.4 (to 5.0×10.sup.4) cells per well into a 24-well (or 96-well) plate and then cultured for 24 hr under cell culture conditions. The culture medium was discarded, followed by washing with PBS and replacement with new DMEM not containing 10% FBS, after which the cells were treated with a test substance (GHK and GHK-TA) at a predetermined concentration and then cultured for 24 hr. Thereafter, CCK was added to the culture medium in an amount equivalent to 1/10 thereof, followed by measurement at 450 nm using an ELISA reader, and the results thereof are shown in FIG. 3.

[0151] As shown in FIG. 3, a GHK peptide exhibited average cell viability of 82.2% at a concentration of 70 to 200 ppm, and GHK-TA exhibited average cell viability of 100.9% at a concentration of 70 to 200 ppm, and was thus confirmed to be stable.

[0152] 1-3: Measurement of Collagen Content in Cell Line

[0153] Fibroblasts (CCD-986SK) were aliquoted in an amount of 1.0×10.sup.4 to 5.0×10.sup.4 cells per well into a 24-well (or 96-well) plate and then cultured for 24 hr under cell culture conditions. The culture medium was discarded, followed by washing with PBS, after which the cells were treated with a test substance (Tripeptide (GHK), (GHK)-TA prepared in Example 1-3-1-1, Pentapeptide (KTTKS), (KTTKS)-TA prepared in Example 1-3-1-2, Hexapeptide (EEMQRR), and (EEMQRR)-TA prepared in Example 1-3-1-3) and new DMEM was added thereto, followed by culture for 24 hr. The culture supernatant was collected and the amount of collagen was measured as described below according to the guidelines of the Ministry of Food and Drug Safety, and the results thereof are shown in FIG. 4.

[0154] 100 μl of an antibody-PoD conjugate solution was placed in each well, after which the culture solution and a standard solution were added in an amount of 20 μL thereto and cultured at 37° C. for 3 hr. The culture solution was removed from the well, followed by washing four times with 400 μL of a phosphate-buffered saline (PBS). 100 μL of a color development reagent (Procollagen type I peptide EIA kit, Takara Biomedical Co.) was added thereto, followed by culture at room temperature for 15 min, addition with 100 μL of 1 N sulfuric acid, and measurement at 450 nm using an ELISA reader.

[0155] As shown in FIG. 4, in the case of GHK, collagen synthesis and promotion of fibroblasts (CCD-986sk) did not occur at a concentration of 80 ppm or less, but sulfhydryl GHK (GHK-TA) exhibited superior collagen synthesis and promotion effects even at a concentration of 70 to 80 ppm. Thus, the peptides of GHK and sulfhydryl GHK (GHK-TA) were composed of the same amino acid sequence, but when the sulfhydryl group was introduced, GHK-TA exhibited the function thereof at a low concentration of 70 to 100 ppm, whereas GHK exhibited efficacy thereof at a relatively high concentration.

[0156] In the case of KTTKS, the collagen synthesis and promotion effects increased in proportion to the concentration up to 50 to 200 ppm, and the effects of sulfhydryl KTTKS (KTTKS-TA) were vastly superior compared to KTTKS.

[0157] In the case of EEMQRR, it was found that the use of thioglycolic acid (TA) as the linker exhibited superior collagen synthesis and promotion effects compared to the use of cysteine (CS) as the linker.

[0158] Experimental Example 2: Evaluation of Collagen Synthesis Promotion Capability of Drug-Coated Microneedle

[0159] 2-1: Collagen Production Capability Depending on Linker X having Sulfhydryl (—SH) Functional Group

[0160] 0.3 g of the drug-coated microneedle (GHK-TA-MN, GHK-MPA-MN, GHK-CS-MN) manufactured in Example 1-4 was added with 40 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 840 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in FIG. 5.

[0161] As shown in FIG. 5, the collagen synthesis promotion capability varied depending on the type of linker X having a sulfhydryl (—SH) functional group. This difference is deemed to be due to the molecular weight of the linker having the sulfhydryl (—SH) functional group. For reference, the molecular weight of the linker is in the order of TA<CS<MPA, and CS has an amine group on the side branch.

[0162] 2-2: Collagen Production Capability Depending on Concentration of GSH (Glutathione)

[0163] 0.3 g of the drug-coated microneedle (GHK-MPA-MN, GHK-CS-MN, KTTKS-TA-MN, GHK-TA-MN) manufactured in Example 1-4 was added with 40 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 840 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in FIG. 5.

[0164] Also, 0.3 g of the drug-coated microneedle (GHK-MPA-MN, GHK-CS-MN, KTTKS-TA-MN, GHK-TA-MN) manufactured in Example 1-4 was added with 100 μl of 0.1 M GSH (glutathione) to detach the peptide from the microneedle for 180 min, and the supernatant was then centrifuged, after which intracellular collagen synthesis promotion capability was evaluated in the same manner as in Experimental Example 1-3. The results thereof are shown in FIG. 6.

[0165] As shown in FIG. 6, when using GSH (glutathione) in amounts of 40 μl and 100 μl, the collagen production rates were similar. Therefore, it can be found that, when GSH (glutathione) is present only in the minimum amount necessary to dissociate the disulfide bond, the drug attached to the microneedle can be released, and the effects thereof can be exhibited.

[0166] Preparation Example 1: Cosmetic Containing Drug-Coated Microneedle

[0167] 1-1: Preparation of Ampoule

[0168] A cream was prepared with the composition of Table 3 below.

TABLE-US-00003 TABLE 3 NO Full ingredient list Amount (wt %) 1 Purified water Remainder 2 Glycerin 2.495 3 1,2-Hexanediol 2.102 4 Methyl propanediol 2.000 5 Propanediol 2.000 6 Butylene glycol 0.550 7 Propylene glycol 0.505 8 Spongilla tripeptide-1 0.500 9 Acetyl hexapeptide-8 0.500 10 Copper tripeptide-1 0.500 11 Polysorbate 80 0.500 12 Allantoin 0.200 13 Panthenol 0.100 14 Trehalose 0.100 15 Sodium hyaluronate 0.020 16 Polyglutamic acid 0.015 17 Caviar extract 0.015 18 Phenethyl alcohol 0.010 19 Hydroxyethyl cellulose 0.002 20 Saccharide isomerate 0.005 21 Methionine 0.001 22 Serine 0.001 23 Histidine 0.001 24 Lecithin 0.000 25 SH-oligopeptide-1 0.000 26 Polysorbate 20 0.000 27 Disodium EDTA 0.030 28 Carbomer 0.450 29 Dehydroxanthan gum 0.050 30 Arginine 0.450 31 Fragrance 0.020

[0169] Experimental Example 3: Efficacy of Cosmetic Containing Drug-Coated Microneedle

[0170] The ampoule prepared in Preparation Example 1 (material name: Spongilla tripeptide-1) was gently applied twice a day for 4 weeks (morning and evening) onto the skin in the direction of skin texture in an amount as large as a 100-won coin size, lightly tapped, and allowed to be absorbed into the skin. Skin changes were observed using a microscope on the 2.sup.nd week and the 4.sup.th week of sample application, and the results thereof are shown in FIG. 7.

[0171] As shown in FIG. 7, it was found that the cream containing GHK-TA-MN was excellent in wrinkle reduction effect.

[0172] Although specific embodiments of the present invention have been disclosed in detail above, it will be obvious to those skilled in the art that the description is merely of preferable exemplary embodiments and is not to be construed to limit the scope of the present invention. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

INDUSTRIAL APPLICABILITY

[0173] According to the present invention, a drug-coated microneedle is capable of effectively delivering a drug having excellent functionality but low skin permeability, and is thus useful as a material for functional cosmetics for whitening, wrinkle reduction, inflammation reduction and the like.